Javascript must be enabled to continue!
Oral Nifidepine versus IV labetalol in severe preeclampsia: A randomized control trial
View through CrossRef
Objective: To compare oral Nifidepine and IV labetalol in terms of rapidity of BP control in severe preeclampsia.
Methods: All patients coming to Services Hospital from March 2017 to February 2019 with diagnosis of severe preeclampsia ≥ 24 weeks gestation were randomized to either receive Nifidepine or Labetalol. Primary outcome measure was time taken to control BP and number of doses required. Secondary outcome measures were side effects of drugs, APGAR score, NICU admission and perinatal mortality.
Results: Two hundred four patients were included in trial with 102 patients in each group. Labetalol took 22.6± 13.5minutes and Nifidepine took 22.09± 11.7 minutes to achieve target BP (p>0.05). Labetalol required 2.3± 1.58 doses and Nifidepine 2.2± 1.58 doses to control BP ( p>0.05). No maternal side effects were seen in 86 (84.31%) and 92(90.19%) patients in both groups (p>0.05). Mean gestational age at birth was 34.8 ±2.73weeks in Labetalol and 35.2±2.48 weeks in Nifidepine group (p>0.05). In labetalol group, 43 (42.15%) babies had APGAR Score < 7/10 and 23(22.54%) babies required admission to NICU while in Nifidepine group 42 (41.17%) babies had Apgar score < 7/10 & 30(29.4%) babies were admitted to NICU(p>0.05). There were 21(20.5%) perinatal deaths in labetalol Group-And 19(18.6%) in Nifidepine group (p>0.05)
Conclusion: Oral Nifidepine and IV labetalol are equally efficacious in controlling BP in patients with severe pre eclampsia without any significant side effects.
doi: https://doi.org/10.12669/pjms.36.6.2591
How to cite this:Wasim T, Agha S, Saeed K, Riaz A. Oral Nifidepine versus IV labetalol in severe preeclampsia: A randomized control trial. Pak J Med Sci. 2020;36(6):1147-1152. doi: https://doi.org/10.12669/pjms.36.6.2591
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Pakistan Journal of Medical Sciences
Title: Oral Nifidepine versus IV labetalol in severe preeclampsia: A randomized control trial
Description:
Objective: To compare oral Nifidepine and IV labetalol in terms of rapidity of BP control in severe preeclampsia.
Methods: All patients coming to Services Hospital from March 2017 to February 2019 with diagnosis of severe preeclampsia ≥ 24 weeks gestation were randomized to either receive Nifidepine or Labetalol.
Primary outcome measure was time taken to control BP and number of doses required.
Secondary outcome measures were side effects of drugs, APGAR score, NICU admission and perinatal mortality.
Results: Two hundred four patients were included in trial with 102 patients in each group.
Labetalol took 22.
6± 13.
5minutes and Nifidepine took 22.
09± 11.
7 minutes to achieve target BP (p>0.
05).
Labetalol required 2.
3± 1.
58 doses and Nifidepine 2.
2± 1.
58 doses to control BP ( p>0.
05).
No maternal side effects were seen in 86 (84.
31%) and 92(90.
19%) patients in both groups (p>0.
05).
Mean gestational age at birth was 34.
8 ±2.
73weeks in Labetalol and 35.
2±2.
48 weeks in Nifidepine group (p>0.
05).
In labetalol group, 43 (42.
15%) babies had APGAR Score < 7/10 and 23(22.
54%) babies required admission to NICU while in Nifidepine group 42 (41.
17%) babies had Apgar score < 7/10 & 30(29.
4%) babies were admitted to NICU(p>0.
05).
There were 21(20.
5%) perinatal deaths in labetalol Group-And 19(18.
6%) in Nifidepine group (p>0.
05)
Conclusion: Oral Nifidepine and IV labetalol are equally efficacious in controlling BP in patients with severe pre eclampsia without any significant side effects.
doi: https://doi.
org/10.
12669/pjms.
36.
6.
2591
How to cite this:Wasim T, Agha S, Saeed K, Riaz A.
Oral Nifidepine versus IV labetalol in severe preeclampsia: A randomized control trial.
Pak J Med Sci.
2020;36(6):1147-1152.
doi: https://doi.
org/10.
12669/pjms.
36.
6.
2591
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.
org/licenses/by/3.
0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Related Results
The dose dependency of the alpha‐adrenoceptor antagonist and beta‐ adrenoceptor partial agonist activity of dilevalol and labetalol in man.
The dose dependency of the alpha‐adrenoceptor antagonist and beta‐ adrenoceptor partial agonist activity of dilevalol and labetalol in man.
1. The alpha‐adrenoceptor antagonist, beta 1‐adrenoceptor antagonist and beta 2‐partial agonist activity of dilevalol, a beta‐adrenoceptor antagonist with vasodilating properties a...
International Breast Cancer Study Group (IBCSG)
International Breast Cancer Study Group (IBCSG)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by International Breast Cancer Study Group (IBCSG). Clinical tria...
Serum catestatin level in preeclampsia
Serum catestatin level in preeclampsia
Background/Aim: Preeclampsia, a significant cause of maternal morbidity and mortality, is linked to increased cardiovascular risks. Catestatin regulates cardiovascular function whi...
Comparative efficacy and safety of antihypertensive agents in preeclampsia and gestational hypertension uncontrolled and their long-term effects on offspring
Comparative efficacy and safety of antihypertensive agents in preeclampsia and gestational hypertension uncontrolled and their long-term effects on offspring
Background: Hypertensive disorder of pregnancy (HDP), a common obstetric
complication that seriously threatens maternal and infant health. The
current clinical treatment drugs incl...
Complicaciones asociadas a la preeclampsia en pacientes atendidas en el Hospital de Supe – Lima – 2021
Complicaciones asociadas a la preeclampsia en pacientes atendidas en el Hospital de Supe – Lima – 2021
Objetivo: Determinar las complicaciones asociadas a la preeclampsia en pacientes atendidas en el Hospital de Supe – Lima - 2021 Metodología: Estudio de tipo Observacional, trasvers...
Differences in Hematocrit and Leukocyte Levels in Preeclampsia and Severe Preeclampsia
Differences in Hematocrit and Leukocyte Levels in Preeclampsia and Severe Preeclampsia
Introduction: Preeclampsia is a serious pregnancy complication characterized by hypertension occurring at a gestational age of ≥ 20 weeks. In preeclampsia, hematological changes o...
The dose dependency of the alpha‐ and beta‐adrenoceptor antagonist activity of carvedilol in man.
The dose dependency of the alpha‐ and beta‐adrenoceptor antagonist activity of carvedilol in man.
1. The alpha‐ and beta‐adrenoceptor antagonist activity of carvedilol, a beta‐adrenoceptor antagonist with vasodilating properties, and labetalol were investigated in 10 healthy ma...
Spanish Breast Cancer Research Group (GEICAM)
Spanish Breast Cancer Research Group (GEICAM)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Spanish Breast Cancer Research Group (GEICAM). Clinical trials...

